结合TERT启动子突变优化分化型甲状腺癌的动态风险分层与预后分组
本研究纳入357例无初始远处转移的分化型甲状腺癌患者,将TERT启动子突变整合入动态风险分层(DRS)构建AHR分组系统。中位随访14年,AHR分组越高复发和癌因死亡风险越高,预测结构复发的效能与DRS相当,对长期癌因生存提供临床意义。
要点
- AHR 1-4组10年无复发生存率分别为94.9%、82.7%、50.2%和23.1%(P<0.001)。
- AHR 1-4组10年癌因生存率分别为100.0%、98.7%、94.2%和76.9%(P<0.001)。
- AHR分组预测复发与DRS相当,对长期癌因生存有临床意义。
核心结论
- AHR分组系统是一种简单的二维预后系统,在预测结构复发方面与DRS同样有效,并为无转移分化型甲状腺癌患者的长期癌因生存提供临床意义。
研究设计与样本
- 共纳入357例无初始远处转移的分化型甲状腺癌患者,按DRS分组比较TERT突变型与野生型的无复发生存率,采用Cox回归计算校正风险比(AHR)并推导AHR分组。
主要发现
- 357例患者中,中位随访14年期间发生90例复发和15例癌症相关死亡。
- AHR分组越高复发风险越高,AHR 1、2、3、4组的10年无复发生存率分别为94.9%、82.7%、50.2%和23.1%(P<0.001)。
- AHR分组越高癌症相关死亡风险越高,AHR 1、2、3、4组的10年癌因生存率分别为100.0%、98.7%、94.2%和76.9%(P<0.001)。
- AHR分组与DRS分组预测复发的方差解释比例(PVE)分别为22.4%和18.5%。
- AHR系统与TNM系统预测癌症相关死亡的PVE分别为11.5%和7.4%。
临床怎么用
- 作者认为AHR分组系统在预测结构复发方面与DRS同样有效,并为无转移分化型甲状腺癌患者的长期癌因生存提供临床意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Currently, no recurrence or mortality risk systems consider molecular testing when predicting thyroid cancer outcomes. OBJECTIVE: We developed an integrative prognostic system that incorporates telomerase reverse transcription (TERT) promoter mutations into the recently proposed risk reclassification system after initial therapy [dynamic risk stratification (DRS)] to better categorize and predict outcomes. DESIGN: A total of 357 differentiated thyroid cancer (DTC) patients without initial distant metastasis were enrolled. Among patients with mutated TERT and wild-type, recurrence-free survival (RFS) was compared according to DRS grouping. Cox regression was used to calculate adjusted hazard ratios (AHRs) to derive AHR groups. Performance of the AHR grouping system with respect to prediction of structural recurrence and cancer-specific survival (CSS) was assessed against the current DRS system and the tumor/node/metastasis (TNM) classification. RESULTS: Among 357 patients, there were 90 recurrences and 15 cancer-related deaths during a median of 14 years of follow-up. Patients in higher AHR groups were at higher risk of recurrence (10-year RFS for AHR 1, 2, 3, and 4: 94.9%, 82.7%, 50.2%, and 23.1%; P < 0.001) and cancer-related death (10-year CSS: 100.0%. 98.7%, 94.2%, and 76.9%; P < 0.001). The proportions of variance explained (PVEs) for the ability of AHR and DRS grouping to predict recurrence were 22.4% and 18.5%. PVEs of AHR and TNM system to predict cancer-related deaths were 11.5% and 7.4%. CONCLUSIONS: The AHR grouping system, a simple two-dimensional prognostic system, is as effective as DRS at predicting structural recurrence and provides clinical implication for long-term CSS in patients with nonmetastatic DTC.
引用
- Kim TH, Ki CS, Kim HS, et al. Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations. J Clin Endocrinol Metab. 2017. PMID: 28323925. doi:10.1210/jc.2016-3434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。